PSMA inhibitor-based tracers can basically only be applied in prostate cancer and octreotide-based SSTR-targeting tracers for neuroendocrine tumors (NETs), while targeting FAP allows for a broader application in many different types of cancers, which makes it a more universal pan-tumor target. Here, FOLH1 is linked to cancer.